Application of RP-HPLC for the Estimation of Allopurinol and Its Related Substances in Bulk and Tablet Dosage Form

Ch. Jaswanth Kumar1*, Prachet Pinnamaneni1, Siva Prasad Morla1, K. N. Rajini Kanth1 and Rama Rao Nadendla1

Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur-522034, Andhra Pradesh, India.

Authors’ contributions

This work was carried out in collaboration among all authors. Author CJK* designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors PP and SPM managed the analyses of the study. Authors KNRK and RRN managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i20B31354

Editor(s):
(1) Dr. Mohamed Fathy, Assiut University, Egypt.

Reviewer(s):
(1) Ralitsa Balkanska, Institute of Animal Science, Bulgaria.
(2) D. Santhi Krupa, Vijaya Institute of Pharmaceutical Sciences for Women, India.
(3) Naheed Akhter, Government College University, Faisalabad, Pakistan.

Complete Peer review History: http://www.sdiarticle4.com/review-history/67200

Original Research Article

ABSTRACT

Aims: The main aim of the present study was to develop and validate a simple and cost-effective method for the estimation of allopurinol and its related substances by using RP-HPLC.

Study Design: Estimation of Allopurinol and its related substance in bulk and tablet dosage forms by RP-HPLC.

Place and Duration of Study: Chalapathi Drug Testing Laboratory, Chalapathi Institute of Pharmaceutical Sciences, Chalapathi Nagar, Lam, Guntur-522034 between October 2020 to January 2021.

Methodology: Method development was carried out by using Schimadzu, Prominence-i series LC 3D-Plus autosampler embedded with lab solutions software, equipped with PDA detector using YMC column (150 mm X 4.6 mm, 3 μm) and 0.1M Ammonium acetate buffer as a mobile phase in the ratio of 100% at a flow rate of 1.0 ml/min at a wavelength of 255nm. The developed method was validated according to ICH guidelines.
Results: The linearity was observed in the range of 20-100 µg/ml with a regression ($R^2$) value of 0.999. Developed method was specific with no interactions and accurate with 100.11% for allopurinol and 99.54% for its related substance. The limit of detection for allopurinol was 2 µg/ml and for related substance was 0.0.1 µg/ml. The limit of quantification for allopurinol was 6 µg/ml and for related substance was 0.03 µg/ml respectively. The percentage relative standard deviation was found to be NMT 2 which indicates that the proposed method was precise and robust.

Conclusion: The developed method was simple, precise and accurate and can be successfully employed for the estimation of allopurinol in bulk and tablet dosage form.

Keywords: Allopurinol; related substances; PDA; validation; ICH guidelines.

1. INTRODUCTION

Allopurinol (1H-pyrazolo[3,4-d] pyrimidin-4-ol) is structural isomer of hypoxanthine which is xanthine oxidase inhibitor, commonly used in the treatment of chronic gout associated with pathological conditions like leukemia, inflammation and in cancer medications. The drug is particularly useful in patients with recurrent renal deposition of urates, proliferative disease and malignancies [1-7].

Fig. 1. Allopurinol

Few analytical methods were reported to establish the identity, purity, physical characteristic, and potency of Allopurinol and related substances. The development of analytical method and validation is vital in quality and purity checking of pharmaceuticals. When developed analytical procedure is not much effective, there is a need to develop newer analytical methods. The choice of analytical methodology is based on many considerations such as chemical properties of the analyte and its concentration, sample matrix, the speed and cost of analysis, type of measurement, that is, quantitative or qualitative, and the number of samples. Safety and efficacy of pharmaceutical product are fundamental aspects in drug therapy and these are dependent not only on the intrinsic toxicological properties of active ingredient but also on the impurities and degradation product that it may contain which could be present as a part of finished product. The impurity profile of drug is much important in case of manufacturing drugs of high purity [8-10]. One of the most important fields of activity in modern industrial pharmaceutical research is the estimation of impurity profiles of bulk drug substances. Separation, structure elucidation and quantitative determination of all impurities in drugs are all part of impurity profiling. The latter aspect should be highlighted, since even slight improvements in production technology, starting materials, purification and storage conditions can have a major effect on the impurity profile. Its role in pharmaceutical formulation research and development is also enormous. Impurity profiling is important for ensuring good accuracy, sensitivity, and stability over the life cycle of drugs from the standpoint of quality risk management [11-15].

2. MATERIAL AND METHODS

2.1 Materials

Allopurinol and impurity-A were obtained from Sigma Aldrich. Ausric-100 tablet containing
allopurinol 100 mg was procured from the local market. Reagents and solvents such as orthophosphoric acid, potassium dihydrogen orthophosphate, and HPLC water of analytical grade were procured from National scientific products.

2.2 Instrument

The chromatographic separation was carried out on HPLC Shimadzu 2030C 3D plus with using lab solutions software with photodiode array detector, YMC column (150 mm x 4.6 mm, 3 µm) with ambient temperature.

2.3 Method Development and Validation

2.3.1 Diluent preparation

Diluent was prepared by dissolving 0.3 gms of potassium dihydrogen phosphate in 100 ml of HPLC water and Ph was adjusted to 3 by using orthophosphoric acid.

2.3.2 Mobile phase preparation

Mobile phase was prepared by dissolving 1.7 gm of ammonium acetate in 100ml of water and the solution was filtered using a 0.45micron Millipore filter paper and was sonicated for 10 mins.

2.3.3 Preparation of Allopurinol standard solutions

About 10 mg of Allopurinol was accurately weighed and transferred into a 10 ml clean dry volumetric flask, added 3/4th volume with phosphate buffer, and made up with phosphate buffer. From the above stock solution, 0.1 ml was taken and transferred into another volumetric flask and made up with phosphate buffer (10 µg/ml).

2.3.4 Preparation of impurity-A standard solutions

About 1 mg of impurity-A was accurately weighed and transferred into a 10 ml clean dry volumetric flask, added 3/4th volume with methanol, and made up with methanol. From the stock solution 1 ml was transferred into another 10 ml volumetric flask and made up with methanol and from the above solution 0.1 ml was transferred into another 10 ml volumetric flask and made up with methanol (0.1 µg/ml).

2.3.5 Sample preparation for assay

Accurately 150 mg of tablet powder weighed and transferred into a 10 ml volumetric flask and volume was made up with phosphate buffer. The above 10 ml of the solution was further diluted with 100 ml with phosphate buffer. From the above solution, 6ml was taken and diluted to 100 ml with phosphate buffer. 20 µl of this solution was injected.

2.4 HPLC Method Development

Allopurinol and its related substances in the sample was analyzed by HPLC technique using the optimized conditions given below.

Optimized conditions for HPLC method development:

- Column: YMC (150mm X 4.6mm, 3µm)
- Wavelength: 255 nm
- Flow rate: 1.0 ml/min
- Mobile phase: Acetate buffer-100%
- Run time: 10 mins
- Injection volume: 20 µl

2.4.1 HPLC method validation

The proposed method was validated according to the ICH guidelines which include system suitability, specificity, linearity, accuracy, precision, limit of detection, limit of quantification and robustness. Under the validation study, the following parameters were studied.

System Suitability: HPLC system was optimized as per the chromatographic conditions. Standard solutions of 20 µl were injected six times into the chromatographic system. To ascertain the system suitability for the proposed method, the parameters such as retention time, the number of theoretical plates, resolution, tailing factor, and % RSD were calculated and compared with the standard specification of the system.

Specificity: The specificity of the method was determined by comparing the chromatograms of blank with standard and sample.

Linearity: Linearity was established by triplicate injections of solutions containing standard allopurinol and impurity-A. The linearity range maintained was 20 to 100 µg/ml for allopurinol and 0.1 to 0.5 µg/ml for impurity-A.

Accuracy: Accuracy was performed in triplicate for various concentrations of allopurinol and impurity-A to determine the accuracy of the proposed method. Amount equivalent to 50%, 100% and 150% of the standard amount was
injected into the HPLC system in accordance with the procedure. Accuracy was assessed as the percentage accuracy and mean % recovery.

**Precision:** Six replicate injections of a known concentration of allopurinol and impurity-A have been determined by injecting them into chromatographic system. The peak area of all injections was taken and the standard deviation, % relative standard deviation (% RSD), was calculated.

**Limit of detection and Limit of Quantification:**
The Limit of detection LOD and limit of quantitation LOQ values were calculated from the calibration curves as per the protocol.

### Results and Discussion

**3.1 System Suitability**
The system suitability parameters of allopurinol and impurity-A were within the acceptance limit and these are represented in Tables 1 and 2.

#### Table 1. System suitability parameters of allopurinol and impurity-A

| Injection No | Allopurinol | Impurity-A |
|--------------|-------------|------------|
| Retention time | Peak area   | Retention time | Peak area |
| 1            | 7.176       | 1934687    | 2.977       | 120547     |
| 2            | 7.186       | 1944226    | 2.981       | 120254     |
| 3            | 7.168       | 1938752    | 2.977       | 122596     |
| 4            | 7.097       | 1945568    | 2.966       | 122547     |
| 5            | 7.080       | 1954457    | 2.956       | 121952     |
| 6            | 7.071       | 1945784    | 2.954       | 122456     |
| Mean         |             | 1943912    | 121725      |
| Standard deviation | 6771.537 | 1055.627    |
| %RSD         | 0.35        | 0.87        |

#### Table 2. Data of system suitability

| Parameters                  | Imp-A | Allopurinol |
|-----------------------------|-------|-------------|
| Retention time              | 2.977 | 7.176       |
| Tailing factor              | 1.756 | 1.788       |
| Theoretical plates (USP)    | 2154  | 3564        |
| %RSD                        | 0.87  | 0.35        |

**Discussion:** After system suitability studies results of allopurinol and impurity-A were observed that all the parameters were within the acceptable limit.

**Acceptance Criteria:** The % RSD should be NMT 2.0%

The number of theoretical plates (N) should be NLT 2000.

The Tailing factor (T) should be NMT 2.0.

**Specificity:** The blank solution does not interact with standard and sample so the method is specific, the specificity values are represented in Table 3. Blank, standard, sample chromatograms are represented in the Figs. 3,4,5.
Table 3. Specificity of allopurinol and impurity-A

| Name     | Allopurinol | Impurity-A |
|----------|-------------|------------|
| Blank    | Not detected| Not detected|
| Standard | 7.097       | 2.966      |
| Sample   | 7.097       | 2.966      |

Fig. 3. Blank chromatogram

Fig. 4. Standard chromatogram
Fig. 5. Sample chromatogram

Discussion: There was no interaction of sample, standard with blank, So the method was specific.

Linearity: The method was linear with good correlation coefficient values and these are represented in Table 4 and linearity plots are represented in Figs. 6 and 7.

| Concentration (µg/ml) | Peak area | Concentration (µg/ml) | Peak area |
|----------------------|-----------|-----------------------|-----------|
| 20                   | 665293    | 0.1                   | 38629     |
| 40                   | 1261904   | 0.2                   | 81570     |
| 60                   | 1923036   | 0.3                   | 120982    |
| 80                   | 2609549   | 0.4                   | 166685    |
| 100                  | 3260995   | 0.5                   | 209408    |

\[ R^2 = 0.9997 \]

| Concentration (µg/ml) | Peak area |
|----------------------|-----------|
| Allopurinol          | Impurity-A|

Fig. 6. Linearity plot of allopurinol
Discussion: Five linear concentrations of allopurinol and impurity-A (20-100 µg/ml & 1-5 µg/ml) were injected. Average areas were mentioned above and linearity equations obtained for Allopurinol was \( y = 32570x + 8361.6 \) and impurity-A was \( y = 420177x + 2165.3 \). The correlation coefficient obtained was 0.999 for both allopurinol and impurity-A. Correlation coefficient of allopurinol and impurity-A was found to be within the acceptable limit.

Acceptance criteria: The correlation coefficient \((R^2)\) should be NLT 0.999

Accuracy: The method was accurate with a good % recovery and these results are represented in Tables 5 and 6.

Table 5. Accuracy data of allopurinol

| %level | Standard peak area | Sample peak area | % recovery | Mean % recovery |
|--------|--------------------|------------------|------------|----------------|
| 50%    | 1943912            | 984250           | 101.03     |                |
|        | 1943912            | 974250           | 100.11     |                |
|        | 1943912            | 975250           | 99.99      |                |
|        | 1943912            | 1941357          | 99.82      |                |
| 100%   | 1943912            | 1943760          | 99.86      | 100.11%        |
|        | 1943912            | 1937576          | 99.47      |                |
|        | 1943912            | 2928185          | 100.18     |                |
|        | 1943912            | 2931124          | 100.32     |                |
|        | 1943912            | 2927894          | 100.21     |                |

Table 6. Accuracy data of impurity-A

| %level | Standard peak area | Sample peak area | % recovery | Mean % recovery |
|--------|--------------------|------------------|------------|----------------|
| 50%    | 121725             | 60525            | 99.21      |                |
|        | 121725             | 60745            | 99.68      |                |
|        | 121725             | 60568            | 99.17      |                |
|        | 121725             | 122252           | 100.39     |                |
| 100%   | 121725             | 121524           | 99.70      | 99.54%         |
|        | 121725             | 121789           | 99.85      |                |
|        | 121725             | 181596           | 99.22      |                |
|        | 121725             | 181895           | 99.41      |                |
|        | 121725             | 181569           | 99.25      |                |
Discussion: Three levels of allopurinol and impurity-A accuracy samples were prepared. Triplicate injections were given for each level of accuracy and mean %recovery was obtained as 100.11% for allopurinol and 99.54% for impurity-A respectively. The % recovery for allopurinol and impurity-A were found to be within the acceptable limit.

Acceptance criteria: The mean % recovery at each level should be not less than 98% and not more than 102%.

Precision: The method was precise with %RSD NMT 2 for Intra assay and intermediate precision these results are represented in the Tables 7 and 8.

Table 7. Intra assay precision of allopurinol and impurity-A

| S. No | Allopurinol | Impurity-A |
|-------|-------------|------------|
| 1     | 1934687     | 120547     |
| 2     | 1944226     | 120254     |
| 3     | 1938752     | 122596     |
| 4     | 1945568     | 122547     |
| 5     | 1954457     | 121952     |
| 6     | 1945784     | 122456     |
| Mean  | 1943912     | 121725     |
| SD    | 6771.537    | 1055.627   |
| % RSD | 0.35        | 0.87       |

Discussion: The sample solution for six injections was given and the obtained areas were mentioned above table. Average area, standard deviation, and %RSD were calculated for allopurinol and impurity-A. %RSD obtained as 0.87%,0.37% respectively for Impurity-A and Allopurinol. The %RSD for Allopurinol and impurity-A peaks was found to be within the acceptable limit.

Acceptance criteria: The %RSD for the peak areas should be NMT 2.0.

Table 8. Intermediate precision of allopurinol and impurity-A

| S. No | Allopurinol | Impurity-A  |
|-------|-------------|-------------|
| 1     | 1932454     | 121546      |
| 2     | 1942156     | 120853      |
| 3     | 1935687     | 122458      |
| 4     | 1942458     | 121572      |
| 5     | 1952596     | 121457      |
| 6     | 1944866     | 120540      |
| Mean  | 121404      | 1941706     |
| SD    | 665.163     | 7089.434    |
| % RSD | 0.55        | 0.37        |

Discussion: In robustness conditions like flow rate (0.8 ml/min), flow rate (1.2 ml/min), wavelength (250 nm), wavelength (260 nm) samples were injected in a duplicate manner. The %RSD was calculated and it was found to be NMT 2.

Acceptance criteria: The %RSD for the peak areas should be NMT 2.0.
% Assay: The % assay of allopurinol was found to be within the acceptable limit and results are given in the Table 11.

Table 11. Assay of allopurinol and impurity-A

| Tablet sample | Label claim (mg) | % Assay |
|---------------|------------------|---------|
| Allopurinol   | 100              | 100.04% |

Discussion: % Assay was calculated for allopurinol tablet and it was found to be 100.04%.

Acceptance criteria: The % assay should be 98% - 102%.

4. CONCLUSION

A simple reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the cost-effective estimation of allopurinol and its related substances in the tablet dosage form. The developed method was validated according to ICH (Q2R1) guidelines. The linear response was observed in the range of 20-100 μg/ml for Allopurinol and 0.1 to 0.5 μg/ml for its related substances with regression of 0.9997 and 0.9994 respectively. The proposed method had adequate specificity for the estimation of allopurinol and related substances in the tablet dosage form. The percentage recoveries were found to be within limits of acceptance criteria between the ranges of 98 – 102%. Precision results were found to be within limits and the method was found to be robust with a %RSD limit of NMT 2.0. The results of the assay showed good agreement with the label claim. The method was validated statistically and was applied successfully for the estimation of allopurinol and its related substances.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

We profusely thank the management and staff of Chalapathi institute of pharmaceutical sciences for providing necessary facilities in fulfilling this research and for their continuous support.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: A review. Ann Pharmacother. 1993;27(3):337-43.
2. Elion GB, Koversky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966;15(7):863-80.
3. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106(2):221-6.
4. Murrell GA, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986;11(5):343-53.
5. Scott JT, Hall AP, Grahame R. Allopurinol in treatment of gout. Br Med J. 1966; 2(5509):321-7.
6. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114.
7. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-93.
8. A validated stability indicating RP-UPLC method for the quantitative determination of potential impurities of allopurinol. American journal of health-system pharmacy (AJHP). 2:116-127.
9. Kachave R, Mandlik P, Wakchaure S. A review on analytical methods of antigout agents. 2020;9(1):136-67.

10. Sajan P, Rohit T Patil S, Mantelingu, Rangappa KS, Kumara MN. A validated stability indicating RP-UPLC method for the quantitative determination of potential impurities of Allopurinol, Am J Pharm Heal Res. 2014;2(10):117-127.

11. Görög S, Babják M, Balogh G, Brlik J, Csehi A, Dravecz F, Gasdag M, Horváth P, Laukó A, Varga K. Drug impurity profiling strategies. Talanta. 1997;44(9):1517-26.

12. Du J, Chang Y, Zhang X, Hu C. Development of a method of analysis for profiling of the impurities in phenoxy-methylpenicillin potassium based on the analytical quality by design concept combined with the degradation mechanism of penicillins. J Pharm Biomed Anal. 2020;186:113309.

13. Shah SR, Patel MA, Naik MV, Pradhan PV and Upadhyay UM: Recent Approaches of “Impurity Profiling” in Pharmaceutical Analysis: A review. Int J Pharm Sci Res. 3(10):3603-3617.

14. Dorottya Bartos and Sandor Gorog. Recent advances in the impurity profiling of drugs. Current Pharmaceutical Analysis 2008;4:215.

15. Huguet-Casquero A, López-Méndez TB, Gainza E, Pedraz JL. Development and validation of an eco-friendly HPLC-DAD method for the determination of oleuropein and its applicability to several matrices: olive oil, olive leaf extracts and nanostructured lipid carriers. Green Chemistry. 2020;22(11):3495-505

© 2021 Kumar et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/67200